Your browser doesn't support javascript.
loading
Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization.
Traversi, Claudio; Nuti, Elisabetta; Marigliani, Davide; Cevenini, Gabriele; Balestrazzi, Angelo; Martone, Gianluca; Caporossi, Tomaso; Tosi, Gian Marco.
Affiliation
  • Traversi C; Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 1, 53100, Siena, Italy.
Graefes Arch Clin Exp Ophthalmol ; 253(4): 511-7, 2015 Apr.
Article in En | MEDLINE | ID: mdl-25016478
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Choroidal Neovascularization / Angiogenesis Inhibitors / Myopia, Degenerative / Antibodies, Monoclonal, Humanized Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Graefes Arch Clin Exp Ophthalmol Year: 2015 Document type: Article Affiliation country: Italy Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Choroidal Neovascularization / Angiogenesis Inhibitors / Myopia, Degenerative / Antibodies, Monoclonal, Humanized Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Graefes Arch Clin Exp Ophthalmol Year: 2015 Document type: Article Affiliation country: Italy Country of publication: Germany